ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "hyperuricemia"

  • Abstract Number: 0552 • ACR Convergence 2020

    Fast Food Habits and Serum Urate Change in Young Adults: 15-Year Prospective Cohort Analysis

    Chio Yokose1, Na Lu2, Natalie McCormick1, John Choi3, Yuqing Zhang4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Boston, 4Massachusetts General Hospital, Quincy, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Fast food consumption has strong positive associations with weight gain and insulin resistance. Obesity and insulin resistance are, in turn, strongly associated with elevated…
  • Abstract Number: 0658 • ACR Convergence 2020

    Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations

    Blanka Stiburkova1, Yu Toyoda2, Katerina Pavelcova1, Jana Bohata1, Pavel Ješina3, Yu Kubota2, Tappei Takada2 and Hiroshi Suzuki2, 1Institute of Rheumatology, Prague, Czech Republic, 2Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, 3Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

    Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
  • Abstract Number: 0664 • ACR Convergence 2020

    Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

    Ana B. Arevalo1, Alba Munoz2, Faris Haddadin2, Karan Sud2, Gustavo Contreras2, Shane Murray2, Yousaf Ali2 and Edgar Argulian2, 1Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, 2Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York

    Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
  • Abstract Number: 0667 • ACR Convergence 2020

    Gout Management Beyond Prescription Writing: The Role of the Pharmacist

    Emma Dorris1, Paul Ryan2, Mariosa Kieran3, Nicola Dalbeth4 and Geraldine McCarthy5, 1School of Medicine, Dublin, Dublin, Ireland, 2Mayfield Family Practice, Cork, Cork, Ireland, 3Pharmacy Department, Dublin, Dublin, Ireland, 4University of Auckland, Auckland, New Zealand, 5University College Dublin, Dublin, Dublin, Ireland

    Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…
  • Abstract Number: 0674 • ACR Convergence 2020

    Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan

    Ruriko Koto1, Akihiro Nakajima1, Hideki Horiuchi1 and Hisashi Yamanaka2, 1Teijin Pharma Limited, Tokyo, Japan, 2Sanno Medical Center, Tokyo, Japan

    Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
  • Abstract Number: 0675 • ACR Convergence 2020

    AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers

    Zancong Shen1, Elizabeth Polvent2, Vijay Hingorani2, Andrea Clouser-Roche2, Chris Mikelatis2, Rongzi Yan2, Shunqi Yan2 and Li-Tain Yeh2, 1Arthrosi therapeutics, Laguna Hills, CA, 2Arthrosi Therapeutics Inc, Laguna Hills, CA

    Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
  • Abstract Number: 0685 • ACR Convergence 2020

    The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout

    Herbert S. Baraf1, Hope Rainey2, Peter Lipsky2 and Peter Lipsky3, 1The Ctr for Rheumatology and Bone Research, Wheaton, MD, 2AMPEL BioSolutions LLC., Charlottesville, VA, 3RILITE Foundation, Charlottesville, VA

    Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…
  • Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting

    Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab

    Mats Dehlin1, Andreas Fasth 2, Maximilian Reinhardt 3 and Lennart Jacobsson 4, 1Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, 2Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, 3Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, 4Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden

    Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…
  • Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting

    Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia

    Danica Grujic1, Kateryna Pirzynowska 2, Paulina Szczurek 3, Stefan Pierzynowski 2, Aditi Desphande 4, Olha Drahanchuck 5, Nadia Mosiichuk 6 and Jarek Wolinski 7, 1Allena Pharmaceuticals, Boston, 2Lund University, Anara AB,/SGPlus, Lund, Sweden, 3National Research Institute of Animal Production, Vitanano Sp. z o.o./PROF,, Balice, Poland, 4Allena Pharmaceuticals, Newton, MA, 5Polish Academy of Sciences, Vitanano Sp. z o.o./PROF,, Jablonna, Poland, 6Lund University, Lund, Sweden, 7Polish Academy of Sciences, Vitanano Sp. z o.o./PROF, Jablonna, Poland

    Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…
  • Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting

    AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial

    zancong shen 1, Elizabeth Polvent 2, Vijay Hingorani 3, Shunqi Yan 4, Rongzi Yan 4 and Litain Yeh4, 1Arthrosi Therapeutics, San Diego, CA, 2Arthrosi Therapeutics, Laguna Hills, CA, 3Arthrosi Therapeutics, San Diego, 4Arthrosi Therapeutics, Laguna Hills

    Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…
  • Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting

    Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout

    Blanka Stiburkova1, Yu Toyoda 2, Katerina Pavelcova 3, Martin Klein 4, Tappei Takada 2 and Hiroshi Suzuki 2, 1Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, 2Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, 3Institute of Rheumatology; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
  • Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting

    Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?

    Brittany Frankel1, Grant Hughes 1 and Mark Wener 1, 1University of Washington, Seattle, WA

    Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…
  • Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting

    Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data

    Ruriko Koto1, Akihiro Nakajima 1, Hideki Horiuchi 1 and Hisashi Yamanaka 2, 1Teijin Pharma Limited, Chiyoda-ku, Tokyo, Japan, 2Sanno Medical Center, Minato-ku, Tokyo, Japan

    Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…
  • Abstract Number: 2065 • 2019 ACR/ARP Annual Meeting

    Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017

    Seulkee Lee1, Yeonghee Eun 1, Jiwon Hwang 2, Hoon-Suk Cha 1, Eun-Mi Koh 1, Jaejoon Lee 1 and Hyungjin Kim 1, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 2Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea

    Background/Purpose: Hyperuricemia and anemia may be related in terms of sharing comorbidities such as chronic kidney disease (CKD) and cardiovascular disease. However, to our knowledge,…
  • Abstract Number: 2077 • 2019 ACR/ARP Annual Meeting

    Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained

    Natalie McCormick 1, Na Lu 2, Sharan Rai 3, Chio Yokose 4, Yuqing Zhang 4 and Hyon K. Choi4, 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2Massachusetts General Hosptial, Boston, MA, 3Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: In a seminal BMJ paper (Prior 1986), the Tokelau Island migrant study for gout and hyperuricemia concluded preventive strategies to modify body mass, diet…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.